Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development

By Public Technologies
  • Immunovant reported topline results from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus.
  • The study missed its primary goal, prompting Immunovant to halt development of IMVT-1402 in this indication.
  • Results showed favorable directional signals on several measures, with stronger antibody reductions linked to better clinical responses.
  • Safety and tolerability remained consistent with prior studies, with no new concerns highlighted.
  • Other IMVT-1402 development programs remain on schedule across multiple autoimmune diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832130) on September 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk